ARIA

ARIAD Pharmaceuticals, Inc. Press Releases

$6.61
*  
0.25
3.93%
Get ARIA Alerts
*Delayed - data as of Dec. 18, 2014  -  Find a broker to begin trading ARIA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ARIA After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
12/9/2014 7:35:00 AM - Business Wire
▼-7.29 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
12/9/2014 7:35:00 AM - Business Wire
▼-7.29 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
12/8/2014 7:35:00 AM - Business Wire
▼-9.70 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
11/25/2014 8:45:00 AM - PR Newswire


ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia
11/24/2014 7:35:00 AM - Business Wire


ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
11/6/2014 9:44:00 AM - Business Wire
▲15.36 % Price Change since this news event. The Volume Ratio is 1.65.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD Reports Third Quarter 2014 Financial Results and Development Progress
11/5/2014 7:35:00 AM - Business Wire
▲13.38 % Price Change since this news event. The Volume Ratio is 2.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD to Present at the Stifel 2014 Healthcare Conference
11/4/2014 7:35:00 AM - Business Wire
▲9.26 % Price Change since this news event. The Volume Ratio is 1.24.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Stephane Le-Mounier Appointed President, SKF Automotive
10/27/2014 9:41:00 AM - Business Wire


ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe
10/24/2014 7:35:00 AM - Business Wire
▲15.96 % Price Change since this news event. The Volume Ratio is 0.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results
10/15/2014 7:35:00 AM - Business Wire
▲27.61 % Price Change since this news event. The Volume Ratio is 1.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
10/10/2014 7:44:00 AM - Business Wire
▲14.96 % Price Change since this news event. The Volume Ratio is 1.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology
10/6/2014 7:35:00 AM - Business Wire


ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib
10/2/2014 7:35:00 AM - Business Wire


ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
9/29/2014 7:35:00 AM - Business Wire